United States — Food and Drug Administration & Novartis
12 shared events · Importance 3 · Last updated Sep 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The FDA granted the approval, expanding Pluvicto's use to earlier-stage metastatic prostate cancer, a regulatory decision that broadens treatment options and sets a precedent for radioligand therapies.
Novartis: Novartis received FDA approval to expand Pluvicto's indication to mHSPC, nearly doubling the eligible patient population and reinforcing its leadership in radioligand therapy. This is expected to drive future revenue growth, though the stock dipped 1.45% on the announcement.
Jul 31, 2026 · 6 articles
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
Novartis: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA granted final approval of ANI's ANDA for generic Everolimus Tablets for Oral Suspension, enabling U.S. market entry. The decision is a routine regulatory action with no direct market exposure for the agency itself.
Novartis: Novartis' Afinitor Disperz faces new generic competition from ANI's approved Everolimus Tablets for Oral Suspension. The affected franchise is small relative to Novartis' overall business, so the financial impact is limited.
Sep 23, 2026 · 7 articles
Regulatory
United States — Food and Drug Administration: The FDA granted accelerated approval for TRUTAKNA based on proteinuria reduction, with continued approval contingent on confirmatory data.
Novartis: Novartis' Fabhalta and Vanrafia are among the competitors to TRUTAKNA in IgAN.
Jul 07, 2026 · 6 articles
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration encourages the adoption of advanced manufacturing technologies and continuous production models, reinforcing the shift from reactive to proactive compliance strategies in the pharmaceutical industry.
Novartis: Novartis is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments, showcasing the industry's move towards Pharma 4.0.
Apr 07, 2026 · 8 articles
Business
United States — Food and Drug Administration: The FDA granted priority review to del-zota in DMD44 and is set to meet with Novartis on next steps for del-brax in FSHD, keeping the agency central to the remaining AOC pipeline.
Novartis: Novartis is the central entity of the event; the del-desiran Phase III failure and prior pelacarsen setback erased roughly $30 billion in market value and intensified investor scrutiny of its M&A strategy and pipeline.
Sep 08, 2026 · 21 articles
Business
United States — Food and Drug Administration: Reportedly rejected ITM-11's application over third-party manufacturing issues and approved Telix's Pixclara and Curium's Bexlutry; its approvals gate up to $250 million in milestone payments.
Novartis: Dominant radiopharmaceutical player with Pluvicto and Lutathera faces a more vertically integrated competitor as Telix absorbs ITM's isotope supply and neuroendocrine tumor pipeline.
Sep 21, 2026 · 6 articles
Business
United States — Food and Drug Administration: The FDA granted Fast Track designation to PentixaFor, facilitating its development and regulatory review.
Novartis: Novartis reported strong Pluvicto sales growth, indicating a booming radiopharma market that could benefit PentixaFor's launch.
Jul 15, 2026 · 10 articles
Business
United States — Food and Drug Administration: The FDA approved Palsonify in 2025, enabling its commercial availability. The agency's regulatory decisions are relevant to the value of the acquired assets.
Novartis: Competitor in acromegaly market.
Jul 06, 2026 · 34 articles
Business
United States — Food and Drug Administration: The FDA declined to approve Lantheus' LNTH-2501 application due to manufacturing issues, a setback for Lantheus' pipeline.
Novartis: Novartis is mentioned as the maker of Pluvicto, a competitor to a Lantheus-Eli Lilly therapeutic that was abandoned.
Aug 03, 2026 · 7 articles
Tech
Novartis: Novartis partnered with Dr. Carl H. June, leading to the development and FDA approval of Tisagenlecleucel, the first CAR-T therapy, which significantly boosted the company's position in advanced cancer treatments.
Jun 16, 2026 · 8 articles
60
Novartis filed for approval United States — Food and Drug AdministrationNovartis del-desiran Phase...
40
Novartis planning FDA meeting United States — Food and Drug AdministrationNovartis del-desiran Phase...
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Novartis interact across events, view sentiment trends, and discover connected entities.
Open Dashboard